statin

Generic Name: statin

Clinical Trials

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Not Applicable

Not yet recruiting

Conditions: Acute Coronary Syndrome
Non ST Segment Elevation Acute Coronary Syndrome

Interventions: Drug: Cholesterol Absorption Inhibitor
Drug: Tafolecimab
Drug: Statin

First Posted Date: 2023-10-24

Last Posted Date: 2023-10-24

Lead Sponsor: China National Center for Cardiovascular Diseases

Target Recruit Count: 3684

Registration Number: NCT06096909

Rosuvastatin and Evolocumab for Coronary Artery Disease

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: statin
Drug: evolocumab

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 195

Registration Number: NCT05984953

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Phase 4

Not yet recruiting

Conditions: Cancer
ASCVD
Atherosclerotic Cardiovascular Disease
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

Interventions: Drug: Statin
Drug: Evolocumab

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Xiang Xie

Target Recruit Count: 620

Registration Number: NCT05976893

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Phase 4

Recruiting

Conditions: Adverse Effect of Cardiovascular Medications (Diagnosis)

Interventions: Drug: Evolocumab combined with statins
Drug: Statin

First Posted Date: 2023-04-06

Last Posted Date: 2023-04-06

Lead Sponsor: Zibo Central Hospital

Target Recruit Count: 60

Registration Number: NCT05802108

Locations: 🇨🇳
Zibo Central Hospital, Zibo, Shandong, China

High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Not Applicable

Recruiting

Conditions: Cardiovascular Diseases
Diabetes Mellitus, Type 2
Coronary Disease

Interventions: Behavioral: phone calls and encouraging patients' lifestyle change and medication adherence
Drug: Statin

First Posted Date: 2023-03-24

Last Posted Date: 2023-12-15

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 16000

Registration Number: NCT05782881

Locations: 🇨🇳
Badong Peolple's Hospital, Enshi, Hubei, China
🇨🇳
Enshi Central Hospital, Enshi, Hubei, China
🇨🇳
Laifeng People's Hospital, Enshi, Hubei, China

and more 104 locations

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Phase 4

Recruiting

Conditions: In-stent Restenosis
Major Adverse Cardiovascular Events

Interventions: Drug: PCSK9 inhibitor
Drug: Statin

First Posted Date: 2022-11-21

Last Posted Date: 2023-11-13

Lead Sponsor: Lin Zhao

Target Recruit Count: 200

Registration Number: NCT05623995

Locations: 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China

Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

Phase 4

Conditions: Acute Coronary Syndrome

Interventions: Drug: Statin
Drug: PCSK9 inhibitor

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 100

Registration Number: NCT05298475

Locations: 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Real World Evidence Study of Statin Use in Brazil

Completed

Conditions: Stroke
Diabetes Mellitus
Hypertension
Myocardial Infarction
Cardiovascular Diseases
Dyslipidemias

Interventions: Drug: Statin

First Posted Date: 2022-03-17

Last Posted Date: 2024-05-14

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 2133900

Registration Number: NCT05285085

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

The Impact of Statin Therapy in the Covid-19 Patients

Completed

Conditions: COVID-19

Interventions: Drug: Statin

First Posted Date: 2022-02-14

Last Posted Date: 2022-02-14

Lead Sponsor: Antalya Training and Research Hospital

Target Recruit Count: 707

Registration Number: NCT05238402

Locations: 🇹🇷
Deniz Demirci, Antalya, Turkey

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Phase 4

Active, not recruiting

Conditions: Myocardial Infarction With Non-Obstructive Coronary Arteries

Interventions: Procedure: Coronary angiography
Diagnostic Test: OCT imaging
Diagnostic Test: Acetylcholine provocative test
Diagnostic Test: TT-Echocardiography
Diagnostic Test: TE/contrast echocardiography
Diagnostic Test: Cardiac magnetic resonance
Diagnostic Test: Circulating biomarkers
Drug: Antiplatelet Drug
Drug: Statin
Drug: Beta blocker
Drug: ACEi/ARB
Drug: CCB
Drug: Nitrates
Drug: Anticoagulant

First Posted Date: 2021-11-17

Last Posted Date: 2024-07-26

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 120

Registration Number: NCT05122780

Locations: 🇮🇹
Centro Cardiologico Monzino, Milan, Italy
🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy